Related News

May 13, 2020

SmarTrend identified an Uptrend for Array Biopharma (NASDAQ:ARRY) on May 21st, 2019 at $24.38. In approximately 12 months, Array Biopharma has returned 96.27% as of today's recent price of $47.85.

In the...

May 6, 2020

SmarTrend identified an Uptrend for Array Biopharma (NASDAQ:ARRY) on May 21st, 2019 at $24.38. In approximately 12 months, Array Biopharma has returned 96.27% as of today's recent price of $47.85.

Array...

April 28, 2020

SmarTrend identified an Uptrend for Array Biopharma (NASDAQ:ARRY) on May 21st, 2019 at $24.38. In approximately 11 months, Array Biopharma has returned 96.27% as of today's recent price of $47.85.

In the...

April 21, 2020

SmarTrend identified an Uptrend for Array Biopharma (NASDAQ:ARRY) on May 21st, 2019 at $24.38. In approximately 11 months, Array Biopharma has returned 96.27% as of today's recent price of $47.85.

In the...

April 13, 2020

SmarTrend identified an Uptrend for Array Biopharma (NASDAQ:ARRY) on May 21st, 2019 at $24.38. In approximately 11 months, Array Biopharma has returned 96.27% as of today's recent price of $47.85.

In the...

April 5, 2020

Below are the three companies in the Biotechnology industry with the lowest betas. Lower-beta stocks mean minimal volatility and are therefore generally considered to be a less risk and offer more stable returns.

NanoViricides Inc ranks...

April 3, 2020

SmarTrend identified an Uptrend for Array Biopharma (NASDAQ:ARRY) on May 21st, 2019 at $24.38. In approximately 11 months, Array Biopharma has returned 96.27% as of today's recent price of $47.85.

In the...

March 29, 2020

Below are the three companies in the Biotechnology industry with the highest debt to equity ratios. The Debt/Equity ratio measures a company's leverage and a high level often implies that a company has financed much of its growth with debt.

...
March 28, 2020

Below are the three companies in the Biotechnology industry with the highest debt to equity ratios. The Debt/Equity ratio measures a company's leverage and a high level often implies that a company has financed much of its growth with debt.

...
March 27, 2020

SmarTrend identified an Uptrend for Array Biopharma (NASDAQ:ARRY) on May 21st, 2019 at $24.38. In approximately 10 months, Array Biopharma has returned 96.27% as of today's recent price of $47.85.

Over the...